FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890004767> ?p ?o ?g. }

• W2890004767 endingPage "1475" @default.
• W2890004767 startingPage "1466" @default.
• W2890004767 abstract "There is limited information about the use of antithrombotic therapies and outcomes of Latin American (LatAm) subjects with atrial fibrillation. The global ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation Atrial Fibrillation–Thrombolysis In Myocardial Infarction 48) trial compared the efficacy and safety of edoxaban versus warfarin over a median follow-up of 2.8 years. The authors aimed to compare adjusted outcomes in Latin America versus outside Latin America and to compare outcomes stratified by anticoagulant treatment and region. The authors analyzed clinical characteristics and outcomes, adjusted for baseline characteristics, the Human Development Index, and randomized treatment of 2,661 LatAm versus 18,444 non–Latin American subjects (nLAS). When compared with nLAS, LatAm subjects had a similar overall risk for stroke. After multivariate adjustment, the risks of stroke/systemic embolism (hazard ratio [HR]: 1.19; 95% confidence interval (CI): 0.96 to 1.47; p = 0.11) and major bleeding (HR: 1.10; 95% CI: 0.89 to 1.36; p = 0.39) were similar in LatAm and nLAS. LatAm subjects were at higher adjusted risk of death (HR: 1.48; 95% CI: 1.30 to 1.69; p < 0.001) and intracranial hemorrhage (ICH) (HR: 1.55; 95% CI: 1.00 to 2.41; p = 0.049). In both regions, when compared with warfarin, edoxaban reduced stroke/systemic embolism (HR: 0.64 and 0.91 in LatAm and nLAS, respectively), major bleeding (HR: 0.71 and 0.82), and cardiovascular death (HR: 0.78 and 0.88), without evidence of regional heterogeneity (pint = 0.41, 0.50, and 0.70, respectively). There was a greater reduction in hemorrhagic stroke with edoxaban in LatAm (HR: 0.16) than in nLAS (HR: 0.64; pint = 0.037). After multivariable adjustment, LatAm subjects with atrial fibrillation had higher rates of intracranial hemorrhage and death than nLAS. Outcomes with higher-dose edoxaban versus warfarin were at least as favorable in LatAm subjects as in nLAS, with an even greater reduction in hemorrhagic stroke seen in LatAm." @default.
• W2890004767 created "2018-09-27" @default.
• W2890004767 creator A5003056448 @default.
• W2890004767 creator A5007468418 @default.
• W2890004767 creator A5010466306 @default.
• W2890004767 creator A5016322021 @default.
• W2890004767 creator A5019612250 @default.
• W2890004767 creator A5021262710 @default.
• W2890004767 creator A5022267024 @default.
• W2890004767 creator A5028971151 @default.
• W2890004767 creator A5045665978 @default.
• W2890004767 creator A5047705809 @default.
• W2890004767 creator A5060647422 @default.
• W2890004767 creator A5082526851 @default.
• W2890004767 creator A5089865834 @default.
• W2890004767 date "2018-09-01" @default.
• W2890004767 modified "2023-10-18" @default.
• W2890004767 title "Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation" @default.
• W2890004767 cites W1964416548 @default.
• W2890004767 cites W1965320794 @default.
• W2890004767 cites W2004592440 @default.
• W2890004767 cites W2022268764 @default.
• W2890004767 cites W2047688972 @default.
• W2890004767 cites W2088387595 @default.
• W2890004767 cites W2096246254 @default.
• W2890004767 cites W2098240323 @default.
• W2890004767 cites W2114775432 @default.
• W2890004767 cites W2147441334 @default.
• W2890004767 cites W2283992568 @default.
• W2890004767 cites W2299398173 @default.
• W2890004767 cites W2464054063 @default.
• W2890004767 cites W2466333440 @default.
• W2890004767 cites W2532640540 @default.
• W2890004767 cites W2598370951 @default.
• W2890004767 cites W2762511873 @default.
• W2890004767 cites W2765673436 @default.
• W2890004767 doi "https://doi.org/10.1016/j.jacc.2018.07.037" @default.
• W2890004767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30236308" @default.
• W2890004767 hasPublicationYear "2018" @default.
• W2890004767 type Work @default.
• W2890004767 sameAs 2890004767 @default.
• W2890004767 citedByCount "9" @default.
• W2890004767 countsByYear W28900047672018 @default.
• W2890004767 countsByYear W28900047672019 @default.
• W2890004767 countsByYear W28900047672020 @default.
• W2890004767 countsByYear W28900047672021 @default.
• W2890004767 countsByYear W28900047672022 @default.
• W2890004767 crossrefType "journal-article" @default.
• W2890004767 hasAuthorship W2890004767A5003056448 @default.
• W2890004767 hasAuthorship W2890004767A5007468418 @default.
• W2890004767 hasAuthorship W2890004767A5010466306 @default.
• W2890004767 hasAuthorship W2890004767A5016322021 @default.
• W2890004767 hasAuthorship W2890004767A5019612250 @default.
• W2890004767 hasAuthorship W2890004767A5021262710 @default.
• W2890004767 hasAuthorship W2890004767A5022267024 @default.
• W2890004767 hasAuthorship W2890004767A5028971151 @default.
• W2890004767 hasAuthorship W2890004767A5045665978 @default.
• W2890004767 hasAuthorship W2890004767A5047705809 @default.
• W2890004767 hasAuthorship W2890004767A5060647422 @default.
• W2890004767 hasAuthorship W2890004767A5082526851 @default.
• W2890004767 hasAuthorship W2890004767A5089865834 @default.
• W2890004767 hasBestOaLocation W28900047671 @default.
• W2890004767 hasConcept C126322002 @default.
• W2890004767 hasConcept C127413603 @default.
• W2890004767 hasConcept C164705383 @default.
• W2890004767 hasConcept C207103383 @default.
• W2890004767 hasConcept C2776301958 @default.
• W2890004767 hasConcept C2777015399 @default.
• W2890004767 hasConcept C2777995511 @default.
• W2890004767 hasConcept C2778661090 @default.
• W2890004767 hasConcept C2779161974 @default.
• W2890004767 hasConcept C2779581417 @default.
• W2890004767 hasConcept C2780290652 @default.
• W2890004767 hasConcept C2780645631 @default.
• W2890004767 hasConcept C44249647 @default.
• W2890004767 hasConcept C500558357 @default.
• W2890004767 hasConcept C71924100 @default.
• W2890004767 hasConcept C78519656 @default.
• W2890004767 hasConceptScore W2890004767C126322002 @default.
• W2890004767 hasConceptScore W2890004767C127413603 @default.
• W2890004767 hasConceptScore W2890004767C164705383 @default.
• W2890004767 hasConceptScore W2890004767C207103383 @default.
• W2890004767 hasConceptScore W2890004767C2776301958 @default.
• W2890004767 hasConceptScore W2890004767C2777015399 @default.
• W2890004767 hasConceptScore W2890004767C2777995511 @default.
• W2890004767 hasConceptScore W2890004767C2778661090 @default.
• W2890004767 hasConceptScore W2890004767C2779161974 @default.
• W2890004767 hasConceptScore W2890004767C2779581417 @default.
• W2890004767 hasConceptScore W2890004767C2780290652 @default.
• W2890004767 hasConceptScore W2890004767C2780645631 @default.
• W2890004767 hasConceptScore W2890004767C44249647 @default.
• W2890004767 hasConceptScore W2890004767C500558357 @default.
• W2890004767 hasConceptScore W2890004767C71924100 @default.
• W2890004767 hasConceptScore W2890004767C78519656 @default.
• W2890004767 hasIssue "13" @default.
• W2890004767 hasLocation W28900047671 @default.
• W2890004767 hasLocation W28900047672 @default.
• W2890004767 hasOpenAccess W2890004767 @default.

• next